Virax Biolabs Group Ltd (VRAX): Next-Year EPS Estimate 40.00%
As of 2026-06-29, Virax Biolabs Group Ltd (VRAX) has a next-year EPS growth estimate of 40.00%.
VRAX was first flagged by our screen on 2026-06-28 with a next-year EPS growth estimate of 40.00%. Current-year growth is projected at 51.60%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 40.00%
- EPS growth this year
- 51.60%
- EPS next quarter (est)
- N/A
- Last price
- $3.26
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-29 | 40.00% | 51.60% | N/A | $3.26 |
| 2026-06-28 | 40.00% | 51.60% | N/A | $3.11 |
Screen Performance
Aggregate stats across all 1825 tickers our top-EPS-revision screen has flagged over the past 91 days.
- Median return since detection
- +5.9%
- % of tickers in the green
- 61%
- Median return on winners
- +21.6%
- Large revisions captured
- 920
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Virax Biolabs Group Ltd's next-year EPS growth estimate?▾
As of 2026-06-29, Virax Biolabs Group Ltd (VRAX) has a next-year EPS growth estimate of 40.00%, based on analyst consensus.
What sector and industry does Virax Biolabs Group Ltd belong to?▾
Virax Biolabs Group Ltd operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. VRAX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Virax Biolabs Group Ltd (VRAX) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports